You are here

Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Roma, , 00161 Italy
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Eighteen years of age or older

2. Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of
the following 7 criteria:

1. Morning stiffness in and around the joints lasting at least 1 hour;

2. Arthritis of 3 or more joint areas;

3. Arthritis of hand joints;

4. Symmetric arthritis. simultaneous involvement of the same joint areas on both
sides of the body;

5. Rheumatoid nodules;

6. Serum Rheumatoid Factor (RF)

7. Radiographic changes. Criteria 1 through 4 must have been present for at least 6
weeks.

3. Patients refractory or without complete response to DMARDs according to the Italian
Guidelines for the clinical practice established by Italian Society of Rheumatology

4. Patients naive to anti-TNF drugs

5. Outpatients

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients involved in controlled or interventional trials in the 12 previous months

NCT00794118
Pfizer
Completed
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study
The primary purpose of this observational study is to describe and define the current daily practice of management of anti-TNF-agents in Rheumatoid Arthritis (RA) patients. Data will be collected only from subjects providing informed consent.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
primary care clinic
Rheumatoid Arthritis
Other: As per clinical practice
As per clinical practice
Other Name: Observational study
1.0
As per routinary clinical practice
Intervention: Other: As per clinical practice
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
299
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Eighteen years of age or older
  2. Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of the following 7 criteria:

    1. Morning stiffness in and around the joints lasting at least 1 hour;
    2. Arthritis of 3 or more joint areas;
    3. Arthritis of hand joints;
    4. Symmetric arthritis. simultaneous involvement of the same joint areas on both sides of the body;
    5. Rheumatoid nodules;
    6. Serum Rheumatoid Factor (RF)
    7. Radiographic changes. Criteria 1 through 4 must have been present for at least 6 weeks.
  3. Patients refractory or without complete response to DMARDs according to the Italian Guidelines for the clinical practice established by Italian Society of Rheumatology
  4. Patients naive to anti-TNF drugs
  5. Outpatients

Exclusion Criteria:

Patients involved in controlled or interventional trials in the 12 previous months

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT00794118
0881A1-102321
B1801119
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now